Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer.

ABSTRACT:

Purpose

Extending adjuvant endocrine therapy (ET) beyond the standard 5 years offers added protection against late breast cancer recurrences in women with early-stage hormone receptor-positive (HR +) breast cancer. Little is known about treatment persistence to extended ET (EET) and the role that genomic assays may play. In this study, we evaluated persistence to EET in women who had Breast Cancer Index (BCI) testing.

Methods

Women with stage I-III HR + breast cancer who had BCI testing after at least 3.5 years of adjuvant ET and ≥ 7 years of follow-up after diagnosis were included (n = 240). Data on medication persistence was based on prescriptions in the electronic health record.

Results

BCI predicted 146 (61%) patients to have low - BCI (H/I)-low - and 94 (39%) pat

SUBMITTER: Foldi J 

PROVIDER: S-EPMC10314405 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature